BazEkon - Biblioteka Główna Uniwersytetu Ekonomicznego w Krakowie

BazEkon home page

Meny główne

Wittelsberger Angela (Innovative Medicines Initiative Executive Office, Brussels), Goldman Michał (Innovative Medicines Initiative Executive Office, Brussels)
Public-Private Collaboration to Advance the Development and Benefit-Risk Assessment of Vaccines: The Innovative Medicines Initiative
Journal of Health Policy and Outcomes Research, 2013, nr 2, s. 12-17, bibliogr. 28 poz.
Słowa kluczowe
Zdrowie, Profilaktyka zdrowotna, Ochrona zdrowia, Choroby
Health, Preventive health care, Health care protection, Illness
The true value of vaccines to public health remains to be fully exploited. Many of the challenges associated with vaccines, such as public distrust in the overall safety of vaccines, or finding standardised approaches to measure vaccine effectiveness, require the involvement of a number of different stakeholders in order to be successfully addressed. Public-private partnerships such as the Innovative Medicines Initiative (IMI) provide a neutral platform that facilitates collaboration on an unprecedented scale between industry, academia, regulators and other actors in the field of vaccine research.(original abstract)
Pełny tekst
  1., Report released August 9, 2013. Available from:; [Accessed: 26.11.2013]
  2. Available from:; [Accessed: 26.11.2013]
  3. Nabel JG. Designing tomorrow's vaccines. N. Engl. J. Med. 2013; 368: 551-560
  4. Kelly DF., Rappuoli R. Reverse vaccinology and vaccines for serogroup B Neiseria meningitides. Adv. Exp. Med. Biol. 2005; 568: 217-223
  5. Mascola JR., Sambor A., Beaudry K., et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J. Virol. 2005; 79: 771-779
  6. Wang S., Kennedy JS., West K., et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008; 26: 3947-3957
  7. Wei CJ., Boyington JC., McTamney PM., et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010; 329: 1060-1064
  8. Nakaya HI., Li S., Pulendran B. Systems vaccinology: learning to compute the behavior of vaccined induced immunity. Rev. Syst. Biol. Med. 2012; 4: 193-205
  9. Child Health Epidemiology Reference Group of WHO and UNICEF. Black R.E., Cousens S., Johnson HL., et al.: Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010; 375: 1969-1987
  10. GVAP document. Available from:; [Accessed: 26.11.2013]
  11. Poland GA., Ovsyannikova IG., Jacobson RM. Application of pharmacogenomics to vaccines. Pharmacogenomics 2009; 10: 837-852
  12. Moxon ER., Siegrist CA. The next decades of vaccines: societal and scientific challenges. The Lancet 2011; 378: 348-359
  13. Mekalanos JJ. Vaccine economics: What price human life? Sci. Transl. Med. 2013; 5: 204ed16
  14. Available from:; [Accessed: 26.11.2013]
  15. Baggs J., Gee J., Lewis E., et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics 2011; 127: S45-S53
  16. The VAESCO case-control study group. Dieleman J., Romio S., Johansen K., et al.: Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ 2011; 343: d3908
  17. The VAESCO consortium. Andrews N., Stowe J., Miller E., et al.: A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark.Vaccine 2012; 30: 3042-3046
  18. Kissling E., Larrauri A., Bella A., et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro surveillance : bulletin Européen sur les maladies transmissibles - European communicable disease bulletin 2013; 18: 1-10
  19. Available from:; [Accessed: 26.11.2013]
  20. Available from:; [Acceseed: 26.11.2013]
  21. The RTS,S Clinical Trials Partnership, A Phase 3 Trial of RTS,C/AS01 Malaria Vaccine in African Infants, N Engl J Med 2012; 367: 2284-2295
  22. EMA/CHMP/VWP/734330/2011
  23. Laurie KL., Huston P., Riley S., et al. Influenza serological studies to inform public health action: best practices to optimise timing, quality and reporting. Influenza Other Respi. Viruses 2012; 1750-2659
  24. Wagner R., Göpfert C., Hammann J., et al. Enhancing the reproducibility of serological methods used to evaluate immunogenicity of pandemic H1N1 influenza vaccines - An effective EU regulatory approach. Vaccine 2012; 30: 4113-4122
  25. Stephenson I., Das R., Wood J., et al. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: An international collaborative study. Vaccine 2007; 25: 4056-4063
  26. Stephenson I., Heath A., Major D., et al. Reproducibility of serologic assays for influenza virus A (H5N1). Emerging Infectious Diseases 2009; 15: 1250-1259
  27. Wood J., Major D., Heath A., et al. Reproducibility of serologic assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO international standard. Vaccine 2012; 30: 210-217
  28. Wood JM., Montomoli E., Newman RW., et al. Collaborative study on influenza vaccine clinical trial serology - part 2: reproducibility study. Pharmeuropa bio & scientific notes 2011; 1: 36-54
Cytowane przez
Udostępnij na Facebooku Udostępnij na Twitterze Udostępnij na Google+ Udostępnij na Pinterest Udostępnij na LinkedIn Wyślij znajomemu